Who is sponsoring NCT05120687?

NCT05120687 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05120687?

Interventions in NCT05120687: noncorticosteroid systemic immunomodulatory therapy (NCSIT).

What condition does NCT05120687 study?

NCT05120687 studies Vogt Koyanagi Harada Disease (VKH).

Is NCT05120687 still recruiting?

NCT05120687 is currently status unknown. Last updated 15 November 2021.

Last reviewed 2021-11-15 · How we verify

NCT05120687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH

Status unknown Last updated 15 November 2021

What this trial tests

trial testing noncorticosteroid systemic immunomodulatory therapy (NCSIT) in Vogt Koyanagi Harada Disease (VKH) in 200 participants. Status unknown.

Timeline

15 October 2021

Primary endpoint
6 October 2024

6 October 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	15 October 2021
Primary completion	6 October 2024
Estimated completion	6 October 2025
Sites	1 location across China

Drugs / interventions tested

noncorticosteroid systemic immunomodulatory therapy (NCSIT) — full drug profile →

Conditions studied

Vogt Koyanagi Harada Disease (VKH) — all drugs for Vogt Koyanagi Harada Disease (VKH) →

Sponsor

Sun Yat-sen University

Who can join

Adults 12 to 70, any sex, with Vogt Koyanagi Harada Disease (VKH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy and safety of corticosteroidcombining noncorticosteroid systemic immunomodulatory therapy (NCSIT) for the treatment of Vogt Koyanagi Harada disease (VKH).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05120687 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 15 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05120687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing